Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Androgen dependency in acquired aplastic anemia.

E A Azen, N T Shahidi

    The American Journal of Medicine
    |August 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    High-resolution genetic mapping of the sucrose octaacetate taste aversion (Soa) locus on mouse Chromosome 6.

    Mammalian genome : official journal of the International Mammalian Genome Society·2001
    Same author

    A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids.

    Clinical therapeutics·2001
    Same author

    A new gene (rmSTG) specific for taste buds is found by laser capture microdissection.

    Mammalian genome : official journal of the International Mammalian Genome Society·2001
    Same author

    Assignment of the proline-rich protein gene Prp2 (alias D6Mit13) to mouse chromosome 6G1 by in situ hybridization.

    Cytogenetics and cell genetics·2000
    Same author

    Sucrose octaacetate avoidance in nontaster mice is not enhanced by two type-A Prp transgenes from taster mice.

    Chemical senses·2000
    Same author

    A frequent mutation in the acidic proline-rich protein gene, PRH2, causing a Q147K change closely adjacent to the bacterial binding domain of the cognate salivary PRP (Pr1') in Afro-Americans. Mutations in brief no. 154. Online.

    Human mutation·2000

    Androgen therapy, specifically oxymetholone, shows benefit in acquired aplastic anemia. Patient blood counts correlated with medication dosage, indicating potential therapeutic value for some individuals.

    Area of Science:

    • Hematology
    • Oncology
    • Pharmacology

    Background:

    • Acquired aplastic anemia is a rare, life-threatening condition characterized by bone marrow failure.
    • Androgen therapy has been explored as a treatment option for acquired aplastic anemia.
    • Understanding the efficacy and patient-specific responses to androgens is crucial for treatment optimization.

    Observation:

    • Three patients with acquired aplastic anemia demonstrated a dependency on androgen therapy.
    • Blood counts, including red cells, neutrophils, and platelets, fluctuated in direct correlation with oxymetholone dosage variations.
    • One patient exhibited differential responses, with red and white cells fluctuating while platelets remained stable relative to oxymetholone therapy.

    Findings:

    • Oxymetholone therapy demonstrated a direct correlation with hematologic parameters in patients with acquired aplastic anemia.

    Related Experiment Videos

  • Hematologic responses were patient-specific, with variations in cell lineages responding to oxymetholone.
  • Dromostanolone did not elicit a hematologic response in two patients, suggesting differential efficacy among androgens.

    • Implications:

    • Androgen therapy, particularly oxymetholone, may offer a beneficial treatment strategy for select patients with acquired aplastic anemia.
    • Further research into androgen mechanisms and patient stratification is warranted to personalize treatment approaches.
    • These findings contribute to the evidence base supporting androgen use in managing acquired aplastic anemia.